ERBB2 and breast carcinoma: To address Wnt-driven triple-negative breast cancer specifically, we focused on the Wnt1 and EGF receptor pathways, since these are 2 predominant drivers of oncogenic signaling in ER- and HER2-negative breast cancers that converge downstream on Myc and Ras effector pathways.